Clinical course and features of soft tissue sarcomas in geriatric patients: a single-center experience

J Int Med Res. 2023 Mar;51(3):3000605231159319. doi: 10.1177/03000605231159319.

Abstract

Objective: This study was performed to examine the disease course in geriatric patients with soft tissue sarcoma and determine the risk factors for mortality.

Methods: We retrospectively analyzed patients who were treated at Istanbul University Oncology Institute from January 2000 to August 2021.

Results: Eighty patients were included in the study. The patients' median age was 69 years (range, 65-88 years). The median overall survival of patients diagnosed between the ages of 65 and 74 years was 70 months, and that of patients diagnosed at the age of ≤75 years was significantly lower at 46 months. The median survival of patients who did and did not undergo surgical resection was 66 and 11 months, respectively, with a significant difference. The median overall survival of patients with positive and negative surgical margins was 58 and 96 months, respectively, also with a significant difference. Age at diagnosis and recurrence/metastasis significantly affected mortality. A 1-year increase in the age at diagnosis increased mortality by 1.147 times.

Conclusion: Age of >75 years, inability to undergo surgery, positive surgical margins, and head and neck location may be associated with a poor prognosis in geriatric patients with soft tissue sarcoma.

Keywords: Soft tissue sarcoma; chemotherapy; geriatric oncology; mortality; prognosis; surgical oncology.

MeSH terms

  • Aged
  • Child
  • Child, Preschool
  • Disease Progression
  • Humans
  • Patients
  • Retrospective Studies
  • Sarcoma* / surgery
  • Soft Tissue Neoplasms* / surgery